ABSTRACT

KEYWORDS

REFERENCES

1. Sackett DL. Rules of evidence and clinical recommendationson the use of antithrombotic agents. Chest 1989;95(suppl):2S-4S.

2. Haas WK, Easton DJ, Adams HP Jr., et al. A randomized trialcomparing ticlopidina hydrochloride with aspirin for lheprevention of stroke in high-risk patients. N Engl J Med1989;321:501-7.

3. Guyatt GH, Sackett DL, Sinclair J, et al. Users’ guides to themedical literature: IX. A method for grading health carerecommendations. JAMA 1995;274:1800-4.

4. Goodnight SH, Cairns JA. Therapeutics use of n-3 fatty acidsfor vascular disease and thrombosis. Chest 1995;108(suppl):302S-4S.

5. Stein PD, Alpert JS, Copeland J, et al. Antithrombotic therapyin patients with mechanical and biological prosthetic heartvalves. Chest 1995;108(suppl):371S-9S.

6. Clagett CP, Anderson FA, Heit J, et al. Prevention of venousthromboembolism. Chest 1995;108(suppl):312S-34S.

7. Atrial Fibrillation Investigators. Risk factors for stroke andefficacy of antithrombotic therapy in atrial fibrillation. ArchIntern Med 1994;1554:1449-57.

8. Laupacis A, Albers GW, Dalen JE, et al. Antithrombotic therapyin atrial fibrillation. Chest 1995;108(suppl):352S-9S.

9. Braitman LE. Confidence intervals assess both clinicalsignificance and statistical significance. Ann Intern Med1991;114:515-7.

10. Guyatt G, Jaeschke R, Heddle N, et al. Basic statistics forclinicians: 2. Interpreting study results: confidence intervals.Can Med Assoc J 1995;152:169-73.

11. Cook DJ, Guyatt GH, Laupacis A, et al. Clinical recommendationsusing levels of evidence for antithrombotic agents. Chest1995; 108(suppl):227S-30S.